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ABSTRACT
The ‘cancer cell fusion’ theory is controversial due to the lack of methods available to identify hybrid cells 
and to follow the phenomenon in patients. However, it seems to be one of the best explanations for both 
the origin and metastasis of primary tumors. Herein, we co-cultured lung cancer stem cells with human 
monocytes and analyzed the dynamics and properties of tumor-hybrid cells (THC), as well as the 
molecular mechanisms beneath this fusion process by several techniques: electron-microscopy, karyotyp-
ing, CRISPR-Cas9, RNA-seq, immunostaining, signaling blockage, among others. Moreover, mice models 
were assessed for in vivo characterization of hybrids colonization and invasiveness. Then, the presence of 
THCs in bloodstream and samples from primary and metastatic lesions were detected by FACS and 
immunofluorescence protocols, and their correlations with TNM stages established. Our data indicate 
that the generation of THCs depends on the expression of CD36 on tumor stem cells and the oxidative 
state and polarization of monocytes, the latter being strongly influenced by microenvironmental fluctua-
tions. Highly oxidized M2-like monocytes show the strongest affinity to fuse with tumor stem cells. THCs 
are able to proliferate, colonize and invade organs. THC-specific cell surface signature CD36+CD14+PANK+ 
allows identifying them in matched primary tumor tissues and metastases as well as in bloodstream from 
patients with lung cancer, thus functioning as a biomarker. THCs levels in circulation correlate with TNM 
classification. Our results suggest that THCs are involved in both origin and spread of metastatic cells. 
Furthermore, they might set the bases for future therapies to avoid or eradicate lung cancer metastasis.
ARTICLE HISTORY 
Received 8 January 2020  
Revised 14 April 2020  
Accepted 10 May 2020 
KEYWORDS 




According to The American Cancer Society, lung cancer is the 
leading cause of cancer-associated deaths.1 Lung cancer is classi-
fied into small-cell (SCLC) and non-small-cell lung carcinoma 
(NSCLC). The latter accounts for more than 85% of cases and 
includes squamous-cell carcinoma, adenocarcinoma and large-cell 
carcinoma. Upon early detection, positive outcomes have 
improved during the last two decades using combinations of 
platinum-based drugs with radiotherapies, and an increase in life 
expectancy of more than 20 years has been achieved. However, 
a substantial proportion of patients – more than 65% – show 
tumor spread already at the time of diagnosis, and 40% of 
NSCLC patients have distant metastases at presentation,2 which 
makes the search for efficient personalized treatments difficult.
Following the ‘seed and soil’ theory, there exists an 
extended consensus in describing metastasis as a process by 
which lost tumor cells, mainly known as circulating tumor 
cells (CTCs)3,4 travel through the bloodstream and the lym-
phatic system, arrive at new “specific organs to their primary 
tumour,” settle, and either colonize it or remain in a quiescent 
state, known as disseminated tumor cells,5,6 until several 
other still unknown stimuli reactivate them to restart coloni-
zation. Though this theory has been deemed reliable in 
explaining the spread of cancer,7 it fails when accounting 
CONTACT Eduardo López-Collazo elopezc@salud.madrid.org IdiPAZ, La Paz University Hospital, Paseo de La Castellana 261 Madrid, 28046, Spain.
Supplemental data for this article can be accessed on the publisher’s website.
ONCOIMMUNOLOGY                                        
2020, VOL. 9, NO. 1, 1–17 
https://doi.org/10.1080/2162402X.2020.1773204
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
for explanations on metastatic cells origin. Viz, the descrip-
tion sounds insufficient due to the presence of a high number 
of “obstacles” and checkpoints that cancer cells released from 
tumors would never be able to pass through on their own. 
Published data in the context of breast cancer indicate that 
CTCs can be reflective of the bulk of primary tumor biomass, 
but do not seed to generate metastases;8 moreover, to fully 
explain recent proof-of-concept of human-CTCs transmigra-
tion through mice blood-brain-barrier, researchers have pos-
tulated the active participation of microglia.9 In fact, most 
current drugs and clinical strategies designed to prevent 
metastasis have failed. Therefore, the grounds on which they 
are based might be incorrect. Probably, the only likely cells 
with required properties for this process, which include 
migration and evasion of immune defense, are immune sys-
tem cells.
In this regard, the hypothesis that potentially metastatic 
cells are originated by leukocyte-tumor cell fusion has been 
taken into consideration during some intervals throughout the 
history of cancer research and then successively abandoned.10- 
12 Most conclusive data reported are from several patients who 
received a bone marrow transplant: all had metastatic cells with 
DNA coming from the cancer-free donor.12–16 In addition to 
this clinical evidence, other authors have reported spontaneous 
hybridization between cells derived from bone marrow 
sarcomas,17,18 lymphoma,19 melanoma,20 breast cancer21,22 
and insulinoma,23 availing the putative role for immune cells 
in this phenomenon. Apparently, myeloid cells are better 
equipped than tumor cells to mediate metastasis. After fused 
with tumor cells, resulting hybrids potentially acquire the 
information required for “tumour behaviour.”24
Our data herein supports the notion that metastasis might 
be due to the fusion of myeloid cells with tumor stem cells, and 
shed light on the molecular mechanisms beneath this fusion, 
positioning CD36 scavenger-receptor as a key molecule on this 
process. A minor fraction of tumor cells with stemness hall-
marks can specifically fuse with macrophages, even in a higher 
proportion than with other cancer cells. In this way, it is 
feasible for tumor cells to reach the bloodstream without any 
obstacles and to pass through checkpoints. Both figuratively 
and literally, it is a type of “Trojan horse” that, with a defense 
system appearance, brings tumor cells to remote sites to colo-
nize other specific organs, in the form of new hybrid cellular 
entities, which we have therefore coined as tumor-hybrid cells 
(THCs), or Trojan horse cells.
Materials and methods
Human samples
All participants provided written informed consent in accor-
dance with ethical guidelines of the 1975 Declaration of 
Helsinki and the Committee for Human Subjects of La Paz 
University Hospital (HULP: PI-3521) and the Clinical 
Research Ethics Committees of the Hospitals of Madrid 
(17.10.1125-GHM). Participants were grouped into healthy 
donors, septic or lung cancer patients. Buffy-coats from healthy 
anonymous donors were supplied by the Transfusion Center of 
the Community of Madrid.
Circulating nucleated cells were isolated after red blood cell 
lysis (BD Biosciences) of whole blood samples. PBMCs and 
plasma from buffy-coats were obtained by Ficoll-Plus gradient 
protocol.25
Mice
Animals were properly housed in temperature- and light- 
regulated rooms with food and water ad libitum. All experi-
mental designs followed the guidelines and were approved by 
the Ethics Committee for Animal Research from La Paz 
University Hospital (CSIC: 733/2018). Humane end-point cri-
teria: suddenly required euthanasia prescribed due to impover-
ished physical conditions.
Cell lines
Human H460 and A549 NSCLC lines were purchased from 
ATCC and cultured in DMEM (Gibco) with 10% FBS, at 37°C 
in a humidified atmosphere with 5% CO2. Puromycin- 
dependent (2.5 µg/mL) H460GFP line was developed.26 
Cancer stem cells (CSCs) from H460/A549 were obtained by 
culture in non-treated Costar plates with selective DMEM/F-12 
(Gibco, 1:1) with 2 mmol/L L-glutamine, 5 mmol/L HEPES, 
0.4% bovine serum albumin, N-2 supplement (Gibco), 20 ng/ 
mL of EFG (PeproTech) and 10 ng/mL bFGF (PeproTech).
A549 CD36-KO/wt pool, CRISPR-engineered for targeting 
the fourth exon of CD36, was purchased from Synthego. Clonal 
expansions were developed and tested for CD36 expression by 
PCR-Sanger sequencing (gDNA level), RT-qPCR (mRNA 
level) and western blot (protein level; sc-70644).
All reagents were endotoxin-free, as assayed with Limulus 
amoebocyte lysate test (Cambrex).
Genomic DNA isolation/amplification
Invitrogen kit (K1820-02) was used after scrapping seeded 
cells. CD36 gene-targetedd region surrounding exon 4 was 
amplified with 5ʹ-GCC TTA AAA TCA ACA GTC GTG 
TCT-3ʹ (forward) and 5ʹ-AGA TTA GGA TTC TAT ACA 
GAC AGG AAA A-3ʹ (reverse) primers. A 540 bp gDNA was 
sequenced by Sanger procedure using an ABIPrism3.1 
sequencer.
Reverse-transcription qPCR
Total RNA was purified by using the High-Pure RNA isolation 
kit (Roche). Gene expression levels were assayed by using 
specific primers shown in Supplemental Table 1.
Western blot assays
Aliquots of 40 μg of protein (Bradford) from cells or vesicles lysates 
were electrophoresed on 10% SDS-PAGE gels, and proteins were 
transferred to 0.2 µm polyvinylidene fluoride membranes (Trans- 
Blot® Turbo™ Midi PVDF Transfer Packs; BIORAD-17041577). 
Then, primary and secondary antibodies incubations were per-
formed, and the signal was detected by an Enhanced 
Chemiluminescent detection kit (BIORAD-17050622), followed 
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by autoradiography. Specific primary antibodies for each experi-
ment are mentioned in corresponding sections.
Flow cytometry
Fluorescence-activated cell sorting (FACS) was performed 
using either BD Biosciences FACSCalibur/FACSCelesta/ 
FACSCanto 3 L or Beckman-Coulter’s Navios flow cytometers 
and raw data analyzed with FlowJo software (Tree Star). 
Sorting and cell collection were performed using either 
Synergy 2 L (Sony) or FACSAria ll (BD Biosciences).
In vitro fusion assay protocol
Unless otherwise indicated, 1.8x105/well PBMC-isolated 
monocytes from buffy-coats were routinely seeded (d0) on 
tissue culture-treated Costar 24-well plates and allowed to 
adhere for 1 h (RPMI), PBS-washed and cultured (RPMI 
+10%FBS) for 16 h before adding CSCs (0.2x105 cells/well), 
thus starting d1 of experimental fusion. Cells were recovered at 
d5 by gentle tip-scraping, and measurement of surface markers 
expression by FACS was performed. Fused populations were 
assessed by gating CD14+GFP+ or CD14+PANK+ (PANK: Pan- 
cytokeratins; Miltenyi 130–080-101) double-positive cells.
In vivo invasiveness and migration assays
Twenty-four nu−/nu− female mice (Charles River, France) were 
i.v. inoculated with either 0.5 × 106 H460GFP-CSC or 
CD14+GFP+ cells, and euthanized after 3, 6 or up to 
28 weeks. Eighteen nu−/nu− female mice were inoculated 
with either CD36+CD14+PANK+ or CD36−CD14+PANK+ 
cells sorted from lung cancer patients’ PBMCs, and let devel-
oping for up to 28 weeks.
Lungs, ganglia and spleens were extracted, and further IHC 
analysis for THCs was performed with anti-human CD14 
(ab45870), PANK (ab9377) and CD36 (Miltenyi 130–108- 
018). Spleens were stained with haematoxylin/eosin and mor-
phology injury average-scored (0–3), after pathologists’ evalua-
tion (ranging 0–3) of parameters:27 i) minimized lymphoid 
follicles, ii) diffuse white pulp and distorted lymphoid archi-
tecture, iii) granular leukocytes in between lymphocytes in 
lymphoid follicles and iv) presence of giant macrophages. 
Thyroid transcription factor-1 expression was performed by 
IHC (TTF-1, DAKO-IR056) and percentage of the total area 
represented by dark-brown dots, calculated with ImageJ.
On the other hand, breast cancer 4T1 cells (105 in 50 µL 
PBS each) or PBS alone as control were injected into the right 
4th inguinal mammary gland of female BALB/c mice. Animals 
were monitored daily for tumor evolution. After 5 weeks, 
blood was collected from the submandibular vein and mice 
were sacrificed. Blood (100 µL) was treated twice with Red 
Blood Cell Lysis Buffer (Sigma) for 5 minutes at RT. 
Remaining cells were stained in cold FACS buffer (PBS, 3% 
FBS, 1 mM EDTA) with a previous incubation with purified 
anti-FcɣRIII/II (2.4G2, TONBO Bioscience) to block Fc- 
receptors. The cocktail of antibodies used included: α-CD45- 
PerPCy5.5, α-Ly6 C-PE, α-Ly6 G-BV450, α-CD11b-PECy7 
(all from BD Biosciences) and α-Cytokeratin-8-Alexa Fluor 
647 (Abcam). In all stains, dead cells were excluded by 
Hoechst 33258 (Invitrogen, Carlsbad, CA) incorporation, 
together with neutrophils (Ly6 G+ cells) to avoid their 
autofluorescence.
Measurement of circulating cells in human peripheral 
blood
BD FACS lysing solution (1 mL of 1X solution; BD Biosciences, 
Cat No. 349202) was added to 500 µL of peripheral blood from 
lung cancer, aneurysm and septic patients, as well as controls, to 
lysate erythrocytes and preserve leukocytes. Tubes were thor-
oughly shaken at RT for 30 minutes, before washing twice with 
PBS. Resulting fixed leukocytes were assessed by FACS with the 
following human antibodies: CD14-PE, CD36-PerCP, CD45- 
APC-Cy7, EpCAM-APC and PANK-FITC. THCs (%) were 
gated as the CD14+ population expressing CD36 and PANK, 
then CD36+CD14+PANK+. This population was further 
assessed for the expression of CD45 and EpCAM, in order to 
compare them to CTCs (CD45−EpCAM+ population).
Organs and tumors immunohistochemistry
Tissues were fixed in 4% paraformaldehyde (SIGMA-P6148), 
embedded in OCT and cut into 10 μm sections with a Leica 
RM2255 microtome (Leica Biosystems). The antibodies- 
stained sections were analyzed by confocal scanning laser 
microscopy, using a Leica SPE laser-scanning microscope 
(Leica Biosystems), and images quantified with ImageJ.
Tissue array immunohistochemistry
Two lung cancer tissue microarrays (TMAs) were purchased 
from Biomax (LC817a) and Abcam (ab178194). The former 
comprises primary tumor and lymph node metastasis whereas 
the latter is a tissue array of progressive lung cancer changes. 
They were stained for CD36 (Abcam, ab23680), CD14 (Abcam, 
ab133335) and PANK, and scored as negative (-) or positive (+) 
for CD36 or CD36/CD14/PANK by two researchers in a blind 
manner.
Vital colorant assays
DID/DIO protocol (Vybrant Multicolor Cell-Labeling kit, 
Fisher) experiments were conducted with human DID- 
monocytes faced to DIO-H460 CSCs, and DIO-H460-CSCs 
/DID-H460 cells competing for monocytes. Fluorescence emis-
sion of DID (665 nm, red) and DIO (501 nm, green) was 
assayed either by FACS or fluorescence microscopy.
Nuclei fusion assessment
Monocytes (1.8x105) from PBMCs were incubated with 10 nM 
EdU (Invitrogen-C10640) for 24 h, whereas H460GFP-CSCs 
were incubated with 0.36 pM DAPI (ROCHE-10236276001) 
for 30 min, before co-cultures. After 5 days, cells were fixed in 
3.7% formaldehyde (SIGMA-252549) and secondary Alexa- 
Fluor647 antibody was added (EdU, Invitrogen-C10640) and 
evaluated by confocal microscopy.
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In vitro migration assay
Corning transwell chambers (8 µm, Sigma) were embedded or 
not with collagen (0.024% in RPMI w/o FBS). Co-cultures, 
monocytes and CSCs were scraped on d5 into RPMI (w/o 
FBS) and seeded (105 cells) on the top compartment of trans-
well chambers; the bottom filled with 700 µL RPMI+10% FBS. 
After 48 h, top and bottom contents were recovered and cell 
migration (M) assessed as the percentage of each cell type in 
the bottom (B) with respect to the total amount seeded in the 
top compartment (A), according to: M = [B/(A + B)]x100. 
A control of 1000 inert beads (Reagent D from Mice CBA, 
BD Biosciences) was used to fit acquisition stop of sample 
collection during FACS.
In vitro proliferation assays
PBMCs (8.1x106) and H460-CSCs (0.9x106) were co-cultured for 
5 days. After labeled, PANK+ tumor cells, CD14+ monocytes and 
PANK+CD14+ hybrids were sorted and a carboxyfluorescein 
succinimidyl ester (CFSE) proliferation assessment protocol 
was performed for each by FACS after 5 days.
Previous sorted cells (103 per well) were also co-cultured 
with CFSE-labeled PBMCs (2x104 per well) isolated from HVs. 
Immune phenotyping of T-cells was analyzed by FACS after 
48 h; cytokines levels on supernatants were measured by cyto-
metric bead array (BD CBA Human Th1/Th2/Th17 Cytokine 
Kit™, BD Biosciences). After 5 days, T-cell proliferation 
induced by pokeweed mitogen (0.5 µg/mL) was also analyzed 
by FACS, in the presence/absence of 1 µg/mL α-CD36 (Abcam, 
ab23680), α-CD39 (Biolgend-328202), α-CD73 (Biolgend- 
344002), α-PD-1 (Bristol-Myers Squibb) and 200 ng/mL α- 
SigleC5 (ThermoFisher PA5-47058) human antibodies.
Automated cell clustering was performed with the viSNE 
algorithm available at Cytobank (www.cytobank.org).28
Single hybrid cells growth monitoring
PANK+CD14+ labeled hybrid cells were sorted and each single 
cell seeded on cRPMI-filled wells of an ultra-low attachment 
(ULA) 96-wells plate. They were let to grow whilst periodic 
serial photos (Leica CTR6000) were taken throughout 20 days 
to register cells development. Eventually, in vitro tumors were 
disaggregated by thorough pipetting, and FACS analyzed for 
the expression of phenotyping epitopes with the following 
human antibodies: CD14-BUV395, CD45-PE-CF594, CD86- 
BUV737, HLA-DR-BV711, CD44-BV786, CD36-PerCP, PD- 
L1-BV421, EpCAM-BV605 and PANK-PE.
Cell imaging video-lapses
Monocytes (2x104 cells/well) were labeled with DID and cul-
tured on a 1μ-Slide 8 Well ibiTreat plate (ibidi, Germany). 
H460-CSCs (2x103 cells) were labeled with DIO, added to DID- 
monocytes, and plates placed on a Cell Observer® Z1 system 
(ZEISS) with standard culture conditions. Fifteen positions were 
selected randomly to take photos at an initial 5 min, and then in 
a 15 min interval during 72 h. Images were qualitatively ana-
lyzed using AxioVision LE 4.8.2.0 software (ZEISS).
A quantitative analysis of populations’ dynamics and fusion 
kinetics was performed by seeding 1.8 × 105 DID-monocytes 
from three HVs and 2 × 104 DIO-H460-CSC cells, in a treated 
24-well clear-film-bottom black plate (Eppendorf). Photos 
were taken every 20 min for the first 24 h, and every 90 min 
after to complete 120 h of video recording. Three fields per well 
were counted for red (DID+-monocytes)/green (DIO+-tumor 
cells)/tangerine (DID+DIO+-hybrids) dots with ImageJ.
In vitro myeloid-tumor cells fusion kinetics
Monocytes were grown for 15 days in order to check their devel-
oping to macrophages by specific antibodies: CD14-BUV395 
(BD-563561), CD15-BV421 (BD-740086) and CD36-PerCP 
(Miltenyi-130 095 480). Simultaneously, the fusion event was 
followed-up with the above markers during the development 
process of both monocytes (d0 to d5) and macrophages (d10 to 
d15).
Neutrophils were isolated from healthy donors using dex-
tran protocol,25 and their development and fusion affinity were 
followed-up for 5 days by specific markers: CD14-BUV395, 
CD15-BV421, CD16-BV480 (BD-566108), CD16b-PE (BD- 
550868), CD36-PerCP and CD66b-PE (Miltenyi-130 104 396).
NK cell expansion, activation and cytolytic activity
K562mbIL15-41BBL feeder cell line (107 cells) was co-cultured 
with 1.5 × 107 PBMCs for 2 weeks in stem cell growth medium 
(Cellgenix), with 10% human male AB serum (Sigma) to obtain 
highly purified NK cells. IL-2 (10 IU/mL) was added for the first 
week and 100 IU/mL thereafter. NK cells were then exposed to 
both sorted GFP+ and CD14+GFP+ cellular entities. After cell 
permeabilization (Cytofix/Cytoperm kit, BD Biosciences), 
CD3−CD56+CD16+ NKs perforin generation was detected with 
specific Perforin-FITC (Miltenyi-130 096 668). Cytotoxicity was 
monitored with conventional 2 h Europium lysis-terpyridine 
dicarboxylic acid (TDA) release assay (Perkin-Elmer). NK (effec-
tor) cells loaded TDA-labeled (target) H460-CSC-GFP+ and 
CD14+GFP+ hybrid cells, at effector-to-target cell ratios of 50:1, 
25:1, 12.5:1 and 6.25:1. Fluorescent measures (ex: 340 nm; em: 
612 nm) were assessed in a BioTek Epoch Microplate 
Spectrophotometer.
Transmission electron microscopy (TEM)
After co-cultures sorting, cells were fixed with 1.5% glutaralde-
hyde in 0.1 M cacodylate buffer (pH 7.4) for 1 h at 4°C and then 
treated with 1% osmium tetroxide (in 0.1 M cacodylate buffer) 
and embedded in epoxy resin. Ultrathin sections were stained 
with uranyl-lead and examined in a JEOL JEM 1010 transmis-
sion electron microscope (JEOL USA, Inc., MA, USA).
RNA-Seq protocol and analysis
Stranded mRNA RNA-Seq libraries were prepared by Vertis 
Biotech (Freising-Weihenstephan, Germany) and sequenced on 
a NextSeq500 device (Illumina) with 75 bp read-length (single 
end). Base calling and demultiplexing were performed with RTA 
Version 2.4.11 and bcl2fastq Version 2.18.0.2, and reads were 
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mapped using the CLC genomics workbench with standard set-
tings and the GRChr38 human reference annotation. The PCA 
analysis was carried out using the R-script prcomp (stats) and the 
rgl package based on row Z-scores of all mRNAs with a mean 
abundance ≥RPKM 1 in at least one cell type. Differentially 
expressed genes were identified using DESeq2 in R (padj 
≤0.001). Heatmaps were generated using JAVATreeView. 
Enriched Kyoto Encyclopedia of Genes and Genomes pathways 
(≥10 genes mapped per pathway) were identified using 
ConsensusPathDB with the gene set “over-representation” and 
“induced network modules” functions. RNA-Seq reads have been 
deposited in the NCBI-GEO (GSE102512).
Karyotype analysis
The three cell types (CD14+ monocytes, GFP+ H460GFP-CSCs 
and CD14+GFP+ hybrids) were cultured according to standard 
techniques on culture slides and harvested. GTG banding was 
used for chromosome analysis. Images were analyzed on 
a Cytovision karyotyping system (Leica).
In vitro modulation of CD36 expression
Highly volatile 4HNE solution (64 mM, Merck) was quickly 
inoculated from −80ºC storage into cRPMI-diluted CSCs, and 
added to seeded monocytes at final concentrations of 10, 20 
and 40 µM, in order to chemically stimulate CD36 expression 
via NRF2 enhancement in both cell types.
Commercial pUNO1-hCD36 (Nucliber) plasmid, hereafter 
pCD36, was used to perform independent transfections of each 
cell type. CSCs (7.5x105 per well) were transfected on d−1 with 
Lipofectamine-LTX (Invitrogen), hereafter Lipo, at a pCD36: 
Lipo ratio of 5 µg:12.5 µL diluted in 1 mL Opti-MEM (Gibco) 
and added to monocytes after 16 h. We assayed two different 
approaches to overexpress CD36 in monocytes: a) transfection 
(d0) at a pCD36:Lipo ratio of 0.5 µg:1.25 µL diluted in 100 µL 
Opti-MEM per well; b) using Transfectosome® (Nanovex 
Biotechnologies SL, Spain) at a pCD36:Transfectosome ratio 
of 0.2 µg:0.6 µL diluted in Opti-MEM per well. A549 wt-CSCs 
and clone B10-CSCs, were also transfected with pCD36 follow-
ing transfectosome protocol.
CD36 downregulation was evaluated with specific human 
CD36 siRNAs: (sense) CACUAUCAGUUGGAACAGAtt, 
(anti-sense) UCUGUUCCAACUGAUAGUGaa; s2647 and 
105938 from Ambion and α-CD36 antibody (ab133625), in 
HiPerFect reagent (Qiagen), hereafter HFT. CSCs (7.5x105 
per well) were transfected with a (siRNA1+ siRNA2):HFT 
ratio of (2.5 µg+2.5 µg):12 µL. For monocytes, a (siRNA1 
+ siRNA2):HFT ratio of (0.5 µg+0.5 µg):6 µL diluted in 
cRPMI per well was used.
In vitro modulation of microenvironment and oxidation/ 
polarization status
We used C11-BODIPY581/591 (ThermoFisher-D3861) 1 µM 
BODIPY (DMSO), hereafter called BODIPY, to measure the 
oxidative status of monocytes’ membranes. For FACS analysis, 
samples were excited using a 488 nm laser, and fluorescence 
emission was collected with 530 nm (FL1) and 585 nm (FL2) 
filters. An FL1/FL2 fluorescence quotient for oxidized/reduced 
BODIPY ratio was calculated.
Effects of oxLDL (ThermoFisher-L34357) and lactate 
(Sigma-07096) on both sole monocytes, and after they had 
been mixed with CSCs, were evaluated for 5 days. oxLDL was 
added on d0 at 50 µg/mL. Lactate (24 mM) was added either at 
d0 or for the last 16 h before the end of the experiment (d5). 
CD163 (BD-556 018) was tested for M2-polarization status.
Standardized monocyte polarization effects on fusion events 
were assayed with IFN-γ (1 ng/106 cells) and IL-4 (40 ng/106 
cells) 48 h prior to facing CSCs (d−2) to achieve, respectively, 
M1 and M2 phenotypes.
We next assessed CD36 on H460GFP–CSCs at 50 µg/mL 
native LDL (ThermoFisher-L3486), in parallel with previously 
studied oxLDL, and anti-oxidative conditions (Tocopherol, 
50 mM, SIGMA-T3251), by using both H460GFP-CSCwt and 
H460GFP-CSC silenced with siRNA-CD36. BODIPY oxidation 
and CD64 (BD555 527) M1-polarization, expressions were 
recorded.
Exosomes isolation and assessment
H460GFP-CSCs were grown as described (the formulation does 
not include FBS, and all components are exosomes-free). 
Monocytes (8x106) from buffy-coats were cultured for 6 days 
with RPMI+10% exosomes-free FBS (Gibco-A25904DG). 
Supernatants were collected and exosomes vesicles (EVs) 
were isolated using a standardized protocol.29
To determine EVs size, nanoparticle tracking analysis was 
performed using a NanoSIGHT LM10 (Malvern, USA) device. 
For western blot analysis, EVs were broken using a solution of 
equal parts of protease inhibitors (Complete protease inhibitor 
cocktail, SIGMA-P8340) and RIPA buffer (ThermoFisher- 
89900). Monoclonal antibodies α-CD63 (ab134045), α-ALIX 
(ab117600) and α-βACTIN (housekeeping, SIGMA-A5316) 
expression were assessed.
Next, 2 × 103 H460GFP-CSC cells were incubated with 5, 10 
or 20 µg of monocytes-exosomes, and 1.8 × 104 monocytes 
(from HVs) were incubated with 5 or 10 µg of H460GFP- 
exosomes, in RPMI+10% exosomes-free FBS. A co-culture of 
2 × 103 H460GFP-CSC and 1.8 × 104 monocytes (cRPMI) was 
run in parallel as control. Hybrids (CD14+PANK+ for mono-
cyte-wells and CD14+GFP+ for tumors-wells) were analyzed by 
FACS after 5 days; note that although PANK and GFP expres-
sion will be driven by tumor cells, putative hybrid formation 
after monocytes incubation with H460GFP-exosomes, could 
only be detected with essential proteins such as PANK.
Statistical analysis
For all the experiments, an adequate sample size was deter-
mined using the results of pilot studies and no statistical 
method was used to determine sample size. Appropriately, 
t-Student, ANOVA followed by Tukey analysis or Mann– 
Whitney U tests were performed. The Chi-square was used to 
evaluate the concordance between PT (primary tumors) and 
M (metastasis) samples and the association between CD36 and 
CD36/CD14/PANK with metastasis. To predict metastasis, 
a logistic regression model was fit with Cohort#1, using 
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circulating THCs (%) and gender (female = 0, male = 1) values 
as explanatory variables. The resulting formula was used to 
derive a simple scoring system: we used the weighted sum of 
the predictors from the logistic regression model multiplied by 
their regression coefficients, and then transformed these onto 
the (0.1) interval to yield a predicted probability of metastasis 
for each patient. Finally, in a validation Cohort#2, we esti-
mated the probability of metastasis based on the formula, by 
examining the area under the curve (AUC) of the Receiver- 
Operating Characteristic (ROC). Thus, AUC measures how 
well the model discriminates between metastatic and non- 
metastatic patients. We also indicated sensitivity, specificity 
and the 95% Confidence Intervals (95% CI). Significance was 
set (*P < .05, **P < .01, ***P < .001, ****P < .0001) using Prism 
6.0 software (GraphPad) and SPSS software (IBM Corp. 
Released 2015. IBM SPSS Statistics for Windows, Version 
23.0. Armonk, NY: IBM Corp).
Results
Generation of hybrids from in vitro fusions between 
monocytes and tumor stem cells
To test the potential implication of fusion events between 
monocytes and CSCs in metastasis, human lung cancer cell 
lines H460GFP, H460 and A549 were cultured in CSC-media 
under non-adherent conditions to drive tumor-initiating char-
acteristics, including the formation of spheroid aggregates 
(Supplemental Figure 1a) and expression of proper markers30 
(Supplemental Figure 1b and 1c). On the other hand, mono-
cytes were isolated from buffy coats, and fusion assays were 
performed as shown in Figure 1a, rendering double-positive 
cells GFP+CD14+ or PANK+CD14+, after a strict doublets 
discrimination (Figure 1b and Supplemental Figure 1d). 
When co-culturing monocytes stained with vital colorant 
DID and H460-CSCs with DIO, double-positive cells defined 
as DID+DIO+ were quickly detected in about 30 minutes by 
confocal microscopy (Figure 1c). As these time-lapses were 
longer quantitatively performed (Supplemental video 1), the 
population’s dynamics showed flat-curve for (non-dividing)- 
monocytes, exponential-curve for (dividing)-tumor cells, and 
(≈16 h)-lag-period followed by an infinite growth for (emer-
ging)-hybrids (Supplemental Figure 2). We detected significant 
differences in the efficiency of hybrids generation between 
CSCs and non-CSCs (Figure 1d). The phenomenon was spe-
cific for monocytes, given that lymphocytes and neutrophils 
co-cultures did not result in hybrids (Figure 1e). Moreover, no 
significant differences were observed neither among mono-
cytes and macrophages nor in monocytes to macrophages 
transition in fusion efficiency, as evaluated by specific markers 
CD14, CD15 and CD3631 (Figure 1e and Supplemental Figure 
3a-e). Note that CD14/CD15/CD36 levels on monocytes and 
neutrophils, and CD16/CD16b/CD66b on neutrophils, were 
analyzed during fusion kinetics monitoring, and fluctuations 
involving fusion event were related only to the former, since 
neutrophils die within the first 24 h of culture and do not 
support any significant proportion to whole fused-population 
(Supplemental Figure 3f-j). Moreover, CD15, the best marker 
describing neutrophils development, should be discarded as it 
is also expressed by most cancer stem-cell lines,32 including 
those in this study (Supplemental Figure 3g). Eventually, 
a similar rate of hybrids was obtained for monocytes and 
macrophages (Figure 1f).
Of note, no changes in fusion rate were observed neither 
when monocytes were cultured in the presence of H460GFP- 
exosomes nor vice-versa (Supplemental Figure 4). Along these 
lines, Gast et al. have described double-positive cells using 
tumor and myeloid cells of murine origin, and neither detected 
phenomenon changes when each of them was cultured in the 
presence of supernatants from the other.12
Tumor-hybrid cells show a well-defined identity
As shown in Figure 2a, multi-nucleated DAPI-labeled H460GFP- 
CSCs co-cultured with EdU-nuclei labeled monocytes generated 
multi-nucleated hybrids cells with fused-nuclei. This finding 
mirrors both karyotype and electron-microscopy analyses of 
hybrids (Figure 2b,c). Although fused-cells preserved tumor- 
like multiple chromosomal aberrations, they showed a normal 
number of chromosomes according to diploid cells. They also 
lost the trisomy at chromosome-16 and an aberrant chromo-
some-A observed in H460 (Figure 2b) thence a key point to 
discriminate between fusion and phagocytosis. Moreover, elec-
tron-microscopy confirmed the fusion process, showing clearly 
morphological H460-different,33 GFP+CD14+-cells of 
10.15 ± 3.05 µm, with pseudopod extensions and lamellipodia, 
large numbers of mitochondria, lysosomes and autophagic 
vacuoles, and often prominent nuclei surrounded by micronu-
clei-containing vacuoles (Figure 2c(i–vi)). Remarkably, electron- 
microscopy also ruled out possible phagocytic events mimicking 
fusion in cytometry analyses. Furthermore, we investigated tran-
scriptome signatures and pathways characteristic of hybrids by 
performing RNA-Seq analysis of naïve CD14+-monocytes 
(CD14+n, blue) and cells resulting from fusion protocol 
(CD14+, red; CD14+GFP+, tangerine and GFP+, green). 
A principal component analysis (PCA) positioned hybrids far 
from CD14+n and in-between CD14+ and GFP+ cells (Figure 2d). 
At the molecular level, this result can be explained by the co- 
occurrence of transcriptional signatures of both cell types in 
hybrids (Figure 2e,f). A thorough analysis of RNA-Seq data 
revealed that, transcripts associated with cancer and expressed 
primarily in GFP+, as well as transcripts involved in immune- 
associated pathways and expressed primarily in CD14+, were 
expressed by hybrids (Supplemental Figure 5a and 5b). 
A number of these genes were validated by RT-qPCR 
(Supplemental Figure 5c). Note also that CD14+ and CD14+n 
cells are quite different at the transcriptomic level (Supplemental 
Figure 6); the former shows a contrasting activated phenotype 
due to their interactions with the CSCs.34
Ultimately, FACS analysis showed that, according to both 
RNA-Seq and CSCs phenotypes (Supplemental Figure 1c and 
Supplemental Figure 5), hybrids were mainly CD14+-cells 
expressing cancer-epithelial-cytokeratins markers (PANK) 
and CD36 (i.e., a CD36+CD14+PANK+ signature, Figure 2g); 
hence, we coined as Tumor-Hybrid Cells (THC).
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Figure 1. Co-culture in vitro of cancer stem cells and human monocytes generates hybrid cells. (a) Pipeline for in vitro fusion assays between cancer stem cells (green) 
and PBMCs’ isolated monocytes (red, CD14+). (b) Representative FACS analysis (n = 9; GFP+ and PANK+, green; CD14+, red) of hybrids yielding after 5 days of fusion 
assays with H460GFP-CSC (tangerine in left panel, GFP+CD14+) and A549-CSC (tangerine in right panel, PANK+CD14+). (c) Representative confocal images of double- 
positive events with vital colorants DIO (green, H460-CSC), DID (red, monocytes) and DAPI for nuclei (blue), after 5 min (i), 15 min (ii), 30 min (iii) and 1 h (iv) of co-culture 
(left panel); arrows indicate double-positive events (co-localization, tangerine), n = 3. In the right panel, the representative image at 1 h (iv) in the left panel, is first 
unmerged for the three channels (v, blue; vi, green; vii, red) and then magnified (4x) to clearly showing merged (viii) colors in a hybrid cell. (d) Representative overlay of 
histograms for FACS analysis of resulting fusions between human monocytes and H460-CSC (green, DIO+) vs. H460 (red, DID+) in the left panel, and A549-CSC (green, 
DIO+) vs. A549 (red, DID+) in the central panel, in a competition assay in which equal quantities of DIO+ and DID+ tumor cells were co-cultured with CD14+ monocytes 
for 5 days (ratio tumor cells:monocytes = 1:10). In the right panel, statistical resume of the results (n = 3; *p < .05, ***p < .001, two-tailed t-test, data are mean ± SD). (e) 
Analysis of resulting fusion events between H460GFP-CSC (left) and A549-CSC (right) with lymphocytes (CD3+), Treg (CD25+ FOXP3+), neutrophils (CD16+) and 
monocytes (CD14+) (for each one, n = 3; **p <.01, ****p < .0001, two-tailed t-test, data are mean ± SD). (f) Analysis of hybrids yielding from fusions between H460GFP- 
CSC (left) and A549-CSC (right) with monocytes or macrophages (bordered bars) after 5 days of co-cultures.
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Figure 2. Fused-cells exhibit a patent entity. (a) Representative confocal images of co-cultures between DAPI-labeledd H460GFP-CSC and EdU-labeled monocytes (630x 
magnification, scale 25 μm): DAPI (blue), EdU plus secondary Alexa-647 (purple), GFP (green). First row: (left) lone control H460GFP-CSCs showing green cytoplasm and 
blue nuclei; (central) lone control monocytes showing purple nuclei; (right) panoramic view of the co-culture. Second row: (left) a co-culture highlighting a fused cell 
close to a tumor cell; (right) 5x zoom of previous framed cells showing blue/purple fused nuclei, with a green cytoplasm. Third row: three other z-axis planes (z1, z3 and 
z5, scale 20 μm) of previous picture highlighting (white arrows) fused nuclei. (b) After fusion, cells were sorted and the karyotype of the different fractions checked 
(CD14+, GFP+ and GFP+CD14+). Differences are marked, salmon circle: losing the trisomy after fusion at the 16 chromosome, clover circle: extra aberrant chromosome A 
that is lost or starts to disappear after fusion. (c) Representative electron-microscopyy photographs: (i) panoramic view of the co-culture, highlighting monocytes (m), 
dying tumor cells (H0), live tumor cells (h) and hybrids (THC); (ii) a fused cell showing dense cytoplasm with heterochromatic nuclei (n), and then magnified (4x) at its left 
side; (iii) a monocyte close to a live tumor cell; (iv) hybrid with prominent nuclei, pseudopod extensions and lamellipodia; (v) a monocyte close to a dying tumor cell with
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CD36 on lung primary tumor is crucial for the generation 
of THCs
Expression of CD36 by CD14+PANK+ hybrids seemed relevant 
as this scavenger-receptor not only had been recently reported to 
play a key role in the context of metastasis,35,36 but also because of 
its known fusogenic activity.37 Moreover, as we moved to evalu-
ate CD36 in H460, we noticed its expression increases either as 
mRNA (Figure 3a) or protein (Figure 3a insert) only in CSC- 
media, as H460 acquired stemness (Supplemental Figure 1). 
Therefore, we passed to assess the role of CD36 expression in 
mediating fusion amongst myeloid and tumor cells. The up- 
regulation of CD36 in both CSCs and monocytes (Figure 3b) 
by hydroxyalkenal activator (4HNE)38 resulted in a significant 
increase of THCs (Figure 3c). CD36 was then separately over-
expressed in monocytes and H460GFP-CSC (Figure 3d). Only for 
H460GFP-CSC transfected with pCD36, an increase in THCs 
events was observed (Figure 3e). However, no significant incre-
ment was found when monocytes overexpressed CD36 by even 
two different protocols (Figure 3f and insert). Consistently, 
though RNA-silencing reduced CD36 expression on both 
H460GFP-CSCs and CD14+-cells (Figure 3g), a significant reduc-
tion of hybrid occurrence was only observed for the former 
(Figure 3h); CD36 downregulation on CD14+-cells did not affect 
fusion rate as much as the presence of α-CD36 (Figure 3h). 
Remarkably, clone A549-B10, a CRISPR-engineered p. 
(Glu46Argfs*7) A549-CD36Δ/Δ cells (Figure 3i and 
Supplemental Figure 7), which consequently did not yield 
THCs if co-cultured with monocytes, was able to rescue normal 
fusion values after transient-transfection with pCD36 (Figure 3j).
Taking into account CD36 affinity for oxidized 
molecules,38–40 we modified monocytes oxidative state by 
intermediate-metabolism manipulation41,42 (Figure 3k), find-
ing that their oxidative boost after oxidizing low-density lipo-
protein (oxLDL) treatment also provoked their polarization to 
M2-phenotype43 (Figure 3l). Likewise, the presence of lactate 
during the last 16 h of fusion-lag induced the same effect on 
monocytes,41–44 in contrast to longer lactate incubation peri-
ods (96 h), which in turn reverted to M1-phenotype (Figure 3l). 
Altogether, the oxidative boost and M2-polarization matched 
the increment in THCs (Figure 3m); note that those CD14+ 
cells that did not fuse in previous experiments showed an M1- 
polarization genotype (Supplemental Figure 6). It is note-
worthy that previous IL4-polarization to M2-monocytes 
increased the hybrids formation ratio (Figure 3n). We observed 
that the oxidative state was also higher for IL4-treated mono-
cytes than both control and IFNγ-treated cells (Figure 3o). 
Other authors have previously reported that M2-phenotype 
favored fusion events.45 As expected, these phenomena were 
closely dependent on microenvironmental oxidative status, 
since native LDL was unable to boost neither oxidized 
(Figure 3p) nor M2-monocytes (Figure 3q). Moreover, CD36- 
silencing for oxidative and non-oxidative microenvironmental 
conditions, and in the presence of tocopherol (a potent anti-
oxidant and inhibitor of CD3646) confirmed this scavenger- 
receptor to be crucial for the fusion event (Figure 3r).
THCs show a high rate of migration and proliferation
To explore whether fusion conferred any advantage to THCs in 
terms of migration and invasiveness, we performed both col-
lagen-free and collagen (membrane) migration assays (Figure 
4a, insert panel). The percentage of migrated cells showed clear 
differences between THCs and CSCs in passive (no membrane) 
and active migration. GFP+CD14+ but not H460GFP-CSCs, 
reached the lower compartment while, as expected, most 
human monocytes migrated through the insert (Figure 4a, 
left panel). Similar findings were obtained with THCs 
(PANK+CD14+) generated from A549 (Figure 4a, right panel).
To test hybrids proliferative ability, CFSE assays were per-
formed and higher proliferation rates of THCs than H460GFP- 
CSCs (Figure 4b) were found. Moreover, after 20 days of sole 
single-cell seeding, a proliferative activity was documented 
(Figure 4c). Interestingly, those in vitro generated tumors 
were quite heterogeneous for a set of tumoral markers (PD- 
L1, EpCAM and cytokeratins), which might be a clue to explain 
metastases heterogeneity, though further in vivo studies will be 
needed (Figure 4c, insert).
Migration ability was also observed in vivo. When inoculat-
ing mice with THCs or H460GFP-CSC, a distribution pattern 
consistent with previous reports,47 after evaluations at 3, 6 and 
28 weeks post injection, was shown (Figure 4d). Most injected 
cells reached the lungs after 3 weeks. However, after 6- and 28- 
weeks THCs but not CSCs were found in lungs and lymph 
nodes, suggesting that THCs were able to colonize and then 
migrate to distant sites. In addition, when we came across 
spleens, a well-known tissue where metastasis by primary 
lung cancer organotropism cannot be justified by circulatory 
pattern,7 we found that those mice inoculated with THCs had 
developed unstructured spleen morphology, with no demar-
cated limits among white and red pulps and THC-lumps devel-
opment with tumor appearance (Supplemental Figure 8); high 
levels of TTF-1 lung cancer-marker expression were detected, 
emphasizing the lung-metastatic features (Supplemental 
Figure 8). Moreover, orthotopic in vivo model of metastasis 
showed that CD45+/Cytokeratin-8+ cells were present in the 
peripheral blood of mice bearing tumor development after 
5 weeks (Supplemental Figure 9). As a whole, these data concur 
with previously reported in mice models showing metastasis- 
relatedd fusion events in mice models.12
THCs avoid immune control
Following the experimental design shown in Figure 5a, we 
moved to study the immune response against hybrids. As 
autophagic vacuoles; (vi) a bi-nuclei hybrid with large numbers of small electron-densee mitochondria, lysosomes, surrounded subcellular organelles and abundant 
rough endoplasmic reticulum. (d) PCA of row Z-scores showing separation of the four cell populations (naïve CD14+, blue; and the resulting cell populations after fusion 
protocol and sorter: CD14+, red; CD14+GFP+, tangerine; GFP+, green) (e) Z-score heat-map showing the major gene clusters (I–IV) (f) Differences among the four cell 
types for clusters (I–IV), mean, **p < .01, ****p < .0001 one-way ANOVA. (g) Protein expression (FACS) of key surface markers to track the cellular components of the 
fusions: THCs (CD36+CD14+PANK+, tangerine), CSC (CD36+CD14−PANK+, green) and monocytes (CD36+CD14+PANK−, red), representative histograms (n = 3).
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Figure 3. Fusion process efficacy depends on both the regulation of CD36 expression by CSCs and microenvironmental lipids fluctuations, and the oxidative status and 
M2-phenotype of MΦs. (a) Relative CD36 mRNA (RT-qPCR) expression of conditioned stem-like H460-CSC vs. native H460 cells, followed-up for 5 days (n = 7, *p = .003, 
one-way ANOVA/Tukey’s); Insert, FACS percentage of CD36+ cells at the end of the assay (n = 7, *p < .05, two-tailed t-test). (b) Overexpression (FACS) of CD36 in both 
CSCs (green) and monocytes (red) by 4HNE (n = 3, *p < .05, **p < .01, ***p < .001, two-tailed t-test). (c) Resulting fusion rates after 4HNE incubation; 40 µM was lethal 
(n = 3, *p = .004, one-way ANOVA/Tukey’s). (d) Specific pCD36 overexpression on CSCs (green) or monocytes (red) ((n = 3, *p = .018, **p = .014, two-tailed t-test). (e) 
Resulting fusion rates with CD36 overexpressing CSCs (brown) or monocytes (light orange) vs. a control co-culture (orange) (n = 3, **p = .005, one-way ANOVA/Tukey’s). 
(f) Two other ways to overexpress CD36 on monocytes (n = 2) and resulting fusion rates with CSCs (n = 2, insert). (g) Specific downregulation of CD36 on CSC (green) or 
monocytes (red) using siRNA-CD36 (n = 3, **p = .0012, ****p = .0001, two-tailed t-test). (h) Effects of siRNA-CD36 combined with α-CD36 and resulting fusion rates 
(n = 6, ****p < .0001, two-tailed t-test). (i, j) CD36 CRISPR-engineered KO abolish fusion event. (i) Increased levels of CD36 protein expression (FACS) by wild type A549- 
CSCs and clone B10, a CRISPR-engineered A549-CD36Δ/Δ–CSC clonal line, after transfection with pCD36 48 h before starting co-cultures with monocytes (n = 4, *p < .05, 
***p < .001, two-tailed t-test). (j) Fusion event is rescued after B10 clone starts overexpressing CD36 (n = 4, **p < .01, two-tailed t-test). (k) Effects of stimulation with
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THCs were exposed to expanded human NK-cells, significant 
downregulation of immune response was observed: perforin 
generation by CD3−CD56+CD16+ cells was reduced48 (Figure 
5b) and cytotoxicity significantly decreased (Figure 5c). Note 
that, hybrids exhibited a higher expression of well-known NK- 
cells inhibitors HLA class I members (HLA-B and HLA-E) than 
CSCs (Supplemental Figure 5). However, though the expression 
of TGF-β was higher in hybrids than CSCs and monocytes 
(Figure 5d), it was no significant enough to explain the effect 
observed in NK-cells.49 Interestingly, both CD4+ and CD8+ 
T-cells showed a marked reduction in mitogen-induced prolif-
eration after exposition to THCs with regards to CSCs (Figure 
5e,f). This effect was reverted in the presence of either α-PD-1 
or a cocktail of α-CD39, α-CD73 and α-SIGLEC5 (Figure 5g,h). 
According to our RNA-Seq analysis, these four molecules exhib-
ited higher expression in hybrids than CSCs (Supplemental 
Figure 5), a pattern that was also verified by FACS (Figure 5i).
In agreement, a differential pro-inflammatory cytokine pro-
duction was observed when hybrids and CSCs were co- 
cultured with PBMCs from HVs (Supplemental Figures 10a 
and 10b). Whilst CSCs up-regulated IFNγ, TNFα and IL-6, 
THCs did not. A global analysis of FoxP3 expression (master 
regulator of Tregcells) by PBMCs, and the immune checkpoints 
PD-1 and CTLA4, indicated an up-regulation of these regula-
tory factors when PBMCs interact with THCs (Supplemental 
Figure 10c, upper panel) with regards to CSCs (Supplemental 
Figure 10c, lower panel). Besides, overexpression of FoxP3 and 
PD-1 on CD4+-lymphocytes, and PD-1 and CTLA4 on CD8+- 
cells were induced by THCs but not by CSCs, as seen after co- 
culturing them with PBMCs (Supplemental Figure 10d). It is 
also noteworthy the differences observed in Treg and CD8+ 
T cells proliferation, after blocking the fusion essential- 
receptor CD36 in co-cultures of HVs’ lymphocytes with either 
CSCs or THCs. According to a mechanism recently reported,50 
CD36-blockade Treg cells were not able to expand in a CSCs’ 
microenvironment (Supplemental Figure 11a) then allowing 
anti-tumoral CD8+ T cells to proliferate (Supplemental Figure 
11b). However, this effect seemed attenuated in THCs’ micro-
environment. Whether or not a metabolic modulation invol-
ving CD36 amongst Treg cells and THCs occurs, will need 
further in vivo studies. Altogether, these data evidence THCs 
are able to both modulate and overcome immune surveillance.
THC-specific markers signature on primary lung tumors 
and in circulation correlate with metastatic events
We next used the signature CD36/CD14/PANK to localize 
“Trojan horses” in tissues and peripheral blood of lung cancer 
patients, looking for a correlation between dissemination pat-
tern and origin of these metastatic cells. Notably, analysis of 
CD36 alone and the triad, along 87 lung samples from normal 
tissue (healthy, n = 4), inflammatory tissue (chronic pneumo-
nia, n = 8) and lung cancer (squamous cell carcinoma, n = 29; 
adenosquamous carcinoma, n = 3; adenocarcinoma, n = 28; 
small-cell carcinoma, n = 9; bronchioloalveolar carcinoma, 
n = 1; large-cellundifferentiated carcinoma, n = 1; and papil-
lary adenocarcinoma, n = 4) revealed high levels of CD36 in 
a number of these samples. However, there was no correlation 
with metastasis occurrence (Chi-square = 2.093, P = .148, 
Person Test) (CD36 columns in Figure 6a, Supplemental 
Figure 12, left panel and Supplemental Table 2). In contrast, 
triple-positive-cells were found only in the lungs of those 
patients who subsequently suffered metastasis (CD36/CD14/ 
PANK columns in Figure 6a, left panel in Figure 6b, CD36/ 
CD14/PANK column in Supplemental Figure 12, and 
Supplemental Table 2). There was a significant correlation 
between CD36/CD14/PANK co-localization in lung samples 
and metastasis occurrence (Chi-square = 36.737, P < .001, 
Pearson test, Supplemental Table 2).
Remarkably, CD36+CD14+PANK+ cells were found in 
60% of the primary tumors of those patients who subse-
quently developed metastasis (40 out of 87 patients) and 
the signature was also found in 80% of the metastatic 
tissues (Figure 6b, Supplemental Figure 12 and 
Supplemental Table 2). Besides, paired samples (primary 
tumors and their corresponding metastases) were not sig-
nificantly different in this regard (n = 40, Chi-square 
= 0.395, P = .530, Supplemental Table 2).
On the other hand, following strategy shown in Supplemental 
Figure 13, presence of THCs was evaluated in circulating cells 
from 50 patients diagnosed with pulmonary tumors (Cohort#1, 
I in Supplemental Table 3) often metastatic, 24 HVs and 20 
septic patients without any clinical history of cancer-related 
pathologies were also analyzed as controls (Figure 6c). THCs 
were not found in controls. However, lung cancer patients were 
positive for CD36/CD14/PANK signature. These patients had 
been diagnosed at a late stage and were included in the study 
before chemotherapy. In agreement, the presence of THCs cor-
related to the size and direct extent of the primary tumor as 
defined by the TNM (Spearman’s Rho = 0.447; P = .006). 
Moreover, when patients were classified into two groups accord-
ing to the median of THC (%) in circulation (Figure 6c and 
Supplemental Figure 14), those patients above the median 
showed significant correlation with size of the primary tumor 
(T, Spearman’s Rho = 0.797; P < .001), spread to regional lymph 
nodes (N, Spearman’s Rho = 0.723; P = .001) and stage 
(Spearman’s Rho = 0.447; P = .025). These results were further 
used to predict the metastatic status of another cohort of 28 
patients with lung cancer (Cohort#2, II in Supplemental 
Table 3), showing that together %THC and gender may predict 
metastasis in a high extent (Supplemental Figure 15; 
AUC = 0.821; 95%CI, 0.679 to 0.963; P < .0001).
oxLDL or lactate (at two time-points of fusion: the last 16 h or a total of 96 h) on monocyte oxidative status (n = 4, *p = .02, one-way ANOVA/Tukey’s). (l) CD163 M2- 
polarization measure of previous monocytes (n = 4, *p = .01, one-way ANOVA/Tukey’s) (m) Resulting fusion rates with previous monocytes (n = 4, *p = .03, one-way 
ANOVA/Tukey’s). (n) Fusion rates reached under canonical (M1) vs. noncanonical (M2) stimulation of monocytes by either IFN-γ or IL-4, respectively (n = 3, ****p = .006, 
one-way ANOVA/Tukey’s). (o) Oxidative status of monocytes on both previous conditions (n = 3, *p = .017, one-way ANOVA/Tukey’s). (p, q) Effects of stimulation with 
LDL or oxLDL, alone or supplemented with tocopherol, as well as the latter alone on monocytes. (p) Oxidative status (n = 3, ***p < .001, two-tailed t-test) and (q) CD64 
expression for M2-polarization measurement on CD14+ cells (n = 3, *p < .05, two-tailed t-test). (r) Effects of downregulate CD36 (siRNA-CD36) on H460-CSCs prior to co- 
culture with monocytes, then stimulating with LDL or oxLDL, alone or supplemented with tocopherol, as well as the latter alone, on hybrids yielding (n = 3, *p < .05, 





Figure 4. THCs show migration and proliferation capabilities both in vitro and in vivo. (a) Active and passive migration of the various populations involved in the fusion 
process. Left insert, a diagram of transwells showing the non-migrated cells (A) in the top chamber, and migrating cells (b) in the bottom chamber. Results for migration 
of fusion assays components from H460GFP-CSC (center) and A549-CSC (right) co-cultures, performed with (left side of each graph) or without a collagen-covered 
membrane (right side of each graph). Hybrids (GFP+CD14+ or PANK+CD14+, for H460GFP or A549, respectivelyy), orange bars; CSCs (idem, GFP+ or PANK+), green bars; 
monocytes, red bars (n = 3, **p < .01, ***p < .001, ****p < .0001, one-way ANOVA/Tukey’s, data are mean ± SD). (B) Proliferation rate differences amongst the three 
sorted cell types as measured by CFSE dimming after 7 days of growth (n = 3, *p =.01, one-way ANOVA/Tukey’s, data are mean ± SD); and a representative diagram of 
proliferative cells (insert). (c) After 5 days, co-cultures of H460GFP-CSC and monocytes were sorted and single hybrids seeded on 96-well plates, then followed-up during 
20 days (a representative experiment is shown, a 1-day single cell is shown 4x magnified; n = 45); Insert, 20 days old tumors expression of several markers (n = 5, data 
are mean ± SD). (d) Mice experimental design (left) for in vivo hybrid invasiveness characterization. Lungs and lymph nodes (right) were analyzed for the presence of 
GFP+ (H460GFP-CSC) and GFP+CD14+ (hybrids) cells after 3, 6 and 28 weeks (n = 5 for each treatment) of i.v. tail inoculation.
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Figure 5. THCs downregulate in vitro immune response. (a) Pipeline of the procedure to study the immune response. Tumor cells (green) were grown to CSC and co- 
cultured with monocytes (red); then,n H460GFP-CSCs (green, GFP+), hybrids (orange, GPP+CD14+) and monocytes (red, CD14+) were sorted and independently seeded 
with either PBMCs or NK cells from HVs. (b, c) Immunogenicity of sorted hybrids vs. H460GFP-CSC, exposed to expanded human NKs, as measured by: (b) perforin 
generation by CD3−CD56+CD16+ cells (n = 4, ****p < .0001, one-way ANOVA/Tukey’s, data are mean ± SD) and (c) lysis at various NK cells:cell ratios (n = 3, **p < .01, 
***p < .001, two-tailed t-test, data are mean ± SD). (d) Protein expression (FACS) of intracellular TGFβ in hybrids (orange), H460GFP-CSCs (green) and monocytes (red); n 
= 5. (e, f) CFSE-labeled PBMCs from HVs were exposed (ratio 1:5) to sorted hybrids (orange, GFP+CD14+), H460GFP-CSC (green, GFP+) and monocytes (red, CD14+): (e) 
representative graphs for mitogen-induced proliferations, defined as CFSEdim, of both CD4+ (left) and CD8+ (right) cells, and (f) statistical resume of the data (n = 4, 
**p < .01, ***p < .001, ****p < .0001 two-tailed t-test, data are mean ± SD). (g, h) CFSE-labeled PBMCs from HVs were stimulated with pokeweed (PWD) and exposed 
(ratio 1:5) to lone sorted hybrids (GFP+CD14+) or added with either αPD-1, αCD39, αCD73, αSigleC5, or a cocktail made of the last three ones: (g) representative graphs 
for proliferations, defined as CFSEdim, of both CD4+ (left) and CD8+ (right) cells, and (h) statistical resume of the data (n = 4, ****p < .0001, two-tailed t-test, data are 
mean ± SD). (i) Protein expression of membrane-anchored CD36, SIGLEC5, CD73, CD39 and PD-L1 (empty black bars) in hybrids (empty orange bar, left of the dotted 

























































































































Figure 6. THCs specific markers signatures in patients with lung cancer. (a) Expression of CD36 and co-localization of the signature CD36/CD14/PANK on lung tissue 
samples from two sets (I and II) of controls, and patients with: non-tumor-related cancer inflammatory disease (inflammatory), adenocarcinoma (AC) and metastatic 
adenocarcinoma (AC*) (representative cases from n = 87; see Supplemental Table 2). (b) Co-localization of the signature CD36/CD14/PANK on primary tumor and 
metastasis samples from patients with metastatic adenocarcinoma (AC*) and squamous carcinoma (SqCC*) (representative cases from n = 87, see Supplemental Table 2 
and Supplemental Figure 12). (c) Percentage of THCs, PANK+CD36+ on gated CD14+ circulating cells from patients with lung adenocarcinoma (n = 50) vs. healthy 
volunteers (HV, n = 20) or patients with sepsis (n = 20) (*p <.0001, one-way ANOVA). Two groups are shown according to median (tangerine dots > median, red dots ≤ 
median), being that above median in significant correlations with primary tumor size (T, ***p < .001), spread to lymph nodes (N, **p = .001) and stage (*p = .025), as 
ranked by Spearman’s coefficient. (d) Percentage of THCs that exhibited the main characteristic of CTCs (CD45−EPCAM+) (****p <.0001, paired t-test). (e) Mice 
experimental design (left) for in vivo invasiveness characterization of THCs (CD36+CD14+PANK+) vs. non-THCs (CD36−CD14+PANK+) cells isolated from lung cancer 
patients’ PBMCs. Spleens (right) were analyzed for histopathological changes (haematoxylin/eosin, H&E), metastatic thyroid transcription factor-1 (TTF-1) expression and
the presence of metastatic THCs (CD36+CD14+PANK+), 28 weeks (n = 3 for each treatment) after inoculation (also see Supplemental Table 4). (f) Schematic diagram of 
the proposed mechanism for Trojan horse cells (THC)-driven metastatic fusion.
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Curiously, THCs ultimately did not exhibit the main mar-
kers of CTCs (CD45−EPCAM+ on THCs gate, Figure 6d, see 
gating strategy in Supplemental Figure 13), reinforcing their 
uniqueness. Finally, when CD36−CD14+PANK+ and 
CD36+CD14+PANK+ subpopulations from lung-cancer 
patients’ PBMCs were inoculated into mice, only the latter 
was found in spleens after 28 weeks, along with unstructured 
morphology and high levels of TTF-1 (Figure 6e and 
Supplemental Table 4).
Discussion
In this study, we have showed that tumors might “exploit” 
myeloid cells to expand toward other organs, following the 
rationale of Paget’s ‘seed and soil’ theory. THCs are able to 
free from primary lung-tumors then exhibiting almost all 
reported hallmarks of both cancer and metastasis,51 including 
motility, microenvironment modulation, genome uniqueness, 
proliferation and active colonization of distant organs – even 
some not explained by the circulatory pattern-. On the other 
hand, though several theories have been proposed to formulate 
the origin of metastatic cells,52 only the “cancer cell fusion” 
theory seems strong enough to explain THCs emergence data, 
by a mechanism (Figure 6f) involving CD36, a scavenger- 
receptor also essential in their dissemination with the proper 
phenotype. Thence, these results grasp an adequate empirical 
support to linking both origin and dissemination pattern of 
metastatic cells in the body.
Our data indicate that fusion between macrophages/mono-
cytes (MΦs) and CSCs takes place with a high dependency on 
CD36 expression by the latter, and polarization and oxidative 
status of MΦs. CD36 in its scavenger-receptor function adapts 
tumor cells to the fluctuating microenvironmental conditions 
mainly related to fuel supply, and through its fusogenic func-
tion recruits major M2-oxidized MΦs to complete fusion pro-
cess for rendering THCs. In agreement with these 
observations, other authors35 have shown that neutralizing 
antibodies against CD36 cause inhibition of metastasis in 
immunocompetent orthotopic mouse models of human oral 
cancer. Altogether, these features open new horizons to explore 
CD36 in both cancer origin and metastasis therapeutics.
Due to the important role of the immune system in the 
elimination of aberrant cells, escaping from immune control 
is crucial for cancer and metastasis. Along these lines, in vitro 
obtained THCs expressed high levels of the immune check-
point ligand PD-L1 and reduced CD8+-lymphocytes prolif-
eration in a PD-L1/PD-1 interaction-dependent manner. 
Other molecules such as SIGLEC5, CD73 and CD39 were 
found overexpressed on THC, albeit only a significant effect 
on the interaction with T cells was observed when these three 
immune-modulators were simultaneously blocked. The pre-
sence of THCs induced a downregulation of NK-cells activity 
and an anti-inflammatory profile in T-cells, together with 
a modulation of Treg cells. Eventually, from in vivo 
approaches, we have learnt that human THCs are able to 
reach and colonize distant sites, and also to circulate in the 
peripheral blood of mice orthotopic metastasis models, hence 
demonstrating their potential to evade the immune 
surveillance.
Previous clinical reports have already supported the theory 
of cancer cell fusion to explain the origins of metastatic cells.12- 
16 Our data demonstrate the presence of THCs in patients with 
lung cancer. The identification of these cells, through CD36/ 
CD14/PANK signature, in lung samples from patients who 
have had metastatic lung tumors, strongly supports a role for 
the hybrids in this context. Furthermore, finding the same 
THCs in their metastases suggests these must travel from the 
primary site to the final stage. These circulating cells have also 
been found in patients with cancer with an outcome of metas-
tasis, but neither in healthy donors nor in patients with an 
unrelated inflammatory pathology. Remarkably, the detection 
of THCs in primary tumors correlated to metastasis incidence 
in the analyzed cohorts. In fact, the frequency of patients with 
CD36/CD14/PANK co-localization in primary tumor and who 
did not develop metastasis was zero. Similar results were 
obtained when we analyzed paired samples of primary tumors 
and metastases from the same patient, and a statistical correla-
tion between the identification of THCs in primary tumors and 
metastatic samples was observed. Besides, we were able to 
predict metastasis occurrence in new lung cancer patients 
based on their circulating THCs and gender. A critical evalua-
tion of these data could indicate that, as well as in primary 
tumors, THCs in metastases could be a result of new fusions 
between tumor and myeloid cells in this niche. Based on our 
data from human samples, we are not able to answer this 
question properly. However, previous reports have suggested 
that patients treated with Denosumab, a potent fusion inhibi-
tor, exhibited a significant reduction of metastasis compared 
with non-treated population;53−55 hence, even in case of de 
novo THCs presentation, our model might remain valid for 
new treatments development.
Finally, it is noteworthy that no influence of either CTCs or 
exosomes could be inferred from our data. Regardless of the 
controversy that several studies have shown a role for both 
CTCs and exosomes in the metastasis fusion context4,56,57 
whilst some others have not,12,58,59 our data did not exclude 
the importance of these two factors. First, we have demon-
strated that THCs are independent events from CTCs but we 
did not dive into properties of the latter since it was not the aim 
of this study. Secondly, despite our findings had indicated that 
THC generation is independent of the presence of exosomes 
derived from their parental lineages, at large exosomes could be 
creating a favored microenvironment to the journey of THCs 
through the circulation to organs they will later colonize.60 
Further research will be then needed to address those open 
questions.
As “white walkers,” THCs are literally a type of ‘Trojan 
horse’ cell that, with its defense system appearance, could 
convey tumor cells to remote sites to colonize other organs, 
avoiding immune system recognition. Our data reinforce the 
extremely complex concept of the metastatic pith and shed 
light on possible improvements in clinical practice to fight 
metastasis.
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